OBM Transplantation (ISSN 2577-5820) is an international peer-reviewed Open Access journal published quarterly online by LIDSEN Publishing Inc., which covers all evidence-based scientific studies related to transplantation, including: transplantation procedures and the maintenance of transplanted tissues or organs; assimilation of grafted tissue and the reconstitution of removed organs or parts of organs; transplantation of heart, lung, kidney, liver, pancreatic islets and bone marrow, etc. Areas related to clinical and experimental transplantation are also of interest.

OBM Transplantation is committed to rapid review and publication, and we aim at serving the international transplant community with high accessibility as well as relevant and high quality content.

The journal publishes all types of articles in English. There is no restriction on the length of the papers. We encourage authors to be concise but present their results in as much detail as necessary, as reviewers are expected to emphasize scientific rigor and reproducibility.

Publication Speed (median values for papers published in 2023): Submission to First Decision: 6.7 weeks; Submission to Acceptance: 14.4 weeks; Acceptance to Publication: 6 days (1-2 days of FREE language polishing included)

Current Issue: 2024  Archive: 2023 2022 2021 2020 2019 2018 2017

Special Issue

Current Advancement of Islet Cell Transplantation in the Treatment of Diabetes Mellitus

Submission Deadline: September 30, 2018 (Closed) Submit Now

Guest Editor

Kenneth L. Brayman, MD, PhD, FACS

Professor of Surgery, Medicine, and Biomedical Engineering, Director of Kidney, Pancreas and Islet Transplant Programs, Director of Center for Cellular Therapy and Biologic Theraputics. Department of Surgery, University of Virginia Health System, 1215 Lee Street, Charlottesville, VA 22908, USA

Website | E-Mail

Research Interests: transplant immunosuppression, chronic allograft nephropathy, solid organ transplantation in patients with HIV, islet cell transplantation, transplantation tolerance, gene therapy and xenotransplantation

About This Topic

OBM Transplantation is an international peer-reviewed Open Access journal, which covers all evidence-based scientific studies related to transplantation. This is seeking original manuscripts for a Special Issue on cell-based therapy for diabetes: “Current Advancement of Islet Cell Transplantation in the Treatment of Diabetes mellitus” scheduled to appear in the first half of 2018.

Islet transplantation and pancreas transplantation have been becoming promising therapies for diabetes, which can restore normal blood glucose and prevent diabetes complications. However, there are many grand challenges for maintaining long-term graft function and insulin independence in diabetes patients.

The special issue will provide a forum for presenting current research works and clinical results showing advancement of cell-based therapy for diabetes, including auto-transplantation, all-transplantation, inflammatory reaction involved islet transplantation, islet macro and microencapsulation, stem cell therapy, as well as in vitro and in vivo imaging of the islets. The special issue will also be open to any author, but mainly invited by guest editor. Each submission will be reviewed by at least two reviewers to ensure a very high quality of papers selected for the Special Issue.

Manuscript Submission Information

Manuscripts should be submitted through the LIDSEN Submission System. Detailed information on manuscript preparation and submission is available in the Instructions for Authors. All submitted articles will be thoroughly refereed through a single-blind peer-review process and will be processed following the Editorial Process and Quality Control policy. Upon acceptance, the article will be immediately published in a regular issue of the journal and will be listed together on the special issue website, with a label that the article belongs to the Special Issue. LIDSEN distributes articles under the Creative Commons Attribution (CC BY 4.0) License in an open-access model. The authors own the copyright to the article, and the article can be free to access, distribute, and reuse provided that the original work is correctly cited.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). Research articles and review articles are highly invited. Authors are encouraged to send the tentative title and abstract of the planned paper to the Editorial Office (transplantation@lidsen.com) for record. If you have any questions, please do not hesitate to contact the Editorial Office.

Welcome your submission!


Open Access Editorial

Islet Transplantation: How Much Have We Advanced and How to Keep Moving Forward?

Received: 11 December 2022;  Published: 19 December 2022;  doi: 10.21926/obm.transplant.2204171
Open Access Review

Islet Identity in Transplantation Procedures: The Intersection of Cellular Maturity and Function

Received: 08 November 2018;  Published: 05 March 2019;  doi: 10.21926/obm.transplant.1901055


Islet transplantation is a promising technique for millions of patients with diabetes, but is severely limited by a shortage of cadaveric donor islets, and more so because of stringent inclusion criteria for organ donation including donor metabolic function, age, and comorbidities. The impact of these diverse factors on islet health have led [...]
Open Access Review

Advances in Human Islet Processing: Manufacturing Steps to Achieve Predictable Islet Outcomes from Research Pancreases

Received: 15 October 2018;  Published: 26 February 2019;  doi: 10.21926/obm.transplant.1901052


Background This presentation of a six-year study processing human islets for research and transplantation includes a review of multi-center transplant studies identifying key variables critical for successful islet processing and defines standardized processing procedures required to provide highly purified, functional Human Islets. Methods [...]
Open Access Review

Targeting Acute Islet Inflammation to Preserve Graft Mass and Long-Term Function

Received: 21 November 2018;  Published: 29 January 2019;  doi: 10.21926/obm.transplant.1901043


Islet transplantation is a minimally invasive cell based replacement therapy to prevent or reverse diabetes or hypoglycemia through natural hormonal responses to regulate blood glucose. However, extending the islet graft functional lifespan remains a challenge that prevents long-term success and widespread use of the procedure. Islets are [...]
Open Access Review

Where’s Waldo? Extrahepatic Site Options for Islet Transplantation

Received: 29 October 2018;  Published: 24 January 2019;  doi: 10.21926/obm.transplant.1901042


The current predominant location for allo- and auto-transplantation of islet cells is into the liver via the portal venous system. Despite the relative success of this site over the last several decades, further study has revealed multiple disadvantages. Portal hypertension, portal vein thrombosis, bleeding, low oxygen tension, instant blood [...]
Open Access Review

Chemical Strategies for Improving Islet Transplant Outcomes

Received: 08 October 2018;  Published: 28 December 2018;  doi: 10.21926/obm.transplant.1804036


Islet transplantation has proven to be a viable treatment for individuals suffering from both Type 1 Diabetes Mellitus (T1D) and chronic pancreatitis. However, a variety of challenges limit the effectiveness of this procedure by reducing the number of islets that survive the harvesting and transplantation processes. Increasing islet survival [...]
Open Access Review

Application of Microfluidic Biochips for Human Islet Transplantation

Received: 08 November 2018;  Published: 21 December 2018;  doi: 10.21926/obm.transplant.1804034


In this review, we discuss the application of microfluidic devices in studying the physiology and pathophysiology of human islets and beta-cells, especially its application for human islet transplantation. Human islet transplantation is a promising therapy for Type I diabetes; however, the islet transplant outcomes for achieving complete insul [...]
Open Access Review

Evolution of Enzyme Requirements for Human Islet Isolation

Received: 24 September 2018;  Published: 07 November 2018;  doi: 10.21926/obm.transplant.1804024


Islet transplantation is becoming an established treatment option for managing a subset of adult patients who have type 1 diabetes mellitus. The success of this procedure is dependent upon the recovery of a sufficient number of functional human islets from donor organs for subsequent transplant. Here, the use of optimized bacterial collagenase [...]
Open Access Original Research

Role of Automated Insulin Delivery (Artificial Pancreas) in Islet Transplantation: An In Silico Assessment

Received: 17 May 2018;  Published: 11 September 2018;  doi: 10.21926/obm.transplant.1803019


Human pancreatic islet transplantation is a minimally-invasive procedure that is gaining recognition for the treatment of type 1 diabetes (T1D). Selected patients with unstable T1D, hypoglycemia unawareness, history of severe hypoglycemia, and glycemic lability, not successfully stabilized with intensive insulin treatment, can be offered this [...]
Open Access Communication

Intrapancreatic Parenchymal Cell Transplantation as a Possible Model for the Development of a Cell-based Therapy for Type I Diabetes Mellitus

Received: 28 March 2018;  Published: 02 August 2018;  doi: 10.21926/obm.transplant.1803016


(1) Background: Transplantation of isolated islets is one of the most powerful approaches to cure insulin-dependent (type I) diabetes mellitus (IDDM). Currently, the most widely used transplantation strategy is percutaneous perfusion into the liver via the portal vein. However, this approach has several drawbacks and is often limited by the [...]
Open Access Case Report

Autoimmunity in Autologous Islet Transplantation

Received: 29 March 2018;  Published: 02 July 2018;  doi: 10.21926/obm.transplant.1803014


Total pancreatectomy (TP) is increasingly being utilized for definitive treatment in patients with debilitating chronic pancreatitis (CP). In an effort to prevent surgical diabetes, the procedure can be performed in conjunction with transplantation of islets of Langerhans recovered from the patients’ own resected pancreas (autologous islet [...]
Open Access Review

Regulation of Inflammatory Response in Islet Transplantation

Received: 29 March 2018;  Published: 22 June 2018;  doi: 10.21926/obm.transplant.1802013


Islet cell transplantation is a developing treatment for patients suffering from severe Type-1 diabetes. The long-term insulin independence after islet cell transplantation has been difficult to achieve, and this has been linked to several factors. One of the major cause of poor long-term outcome is inflammation surrounding the islets. Inflamm [...]
Open Access Case Report

Delayed Clinically Significant Portal Hypertension after Total Pancreatectomy-Islet Auto-Transplantation

Received: 21 March 2018;  Published: 12 June 2018;  doi: 10.21926/obm.transplant.1802011


Portal hypertension has not been described as a complication of total pancreatectomy-islet auto-transplantation (TPIAT). We describe the first reported case of delayed and clinically significant portal hypertension following TPIAT in a patient with idiopathic chronic pancreatitis.
Open Access Review

Stem Cell Strategies to Promote Islet Transplantation Outcomes

Received: 02 April 2018;  Published: 05 June 2018;  doi: 10.21926/obm.transplant.1802010


Pancreas or islet transplantation is the only reliable cure for Type 1 Diabetes. However, shortage of donor tissue supply, longitudinal graft attrition due to innate and adaptive immunity and the recurrence of autoimmunity, as well as the harmful side-effects of chronic immunosuppressive therapy limit the wide-spread acceptance of islet transp [...]
Open Access Review

Islet Xenotransplantation for the Treatment of Type 1 Diabetes

Received: 25 February 2018;  Published: 25 April 2018;  doi: 10.21926/obm.transplant.1802008


Allogeneic islet transplantation has been established to prevent severe hypoglycemia for unstable type 1 diabetic patients. Recent phase 3 clinical trial clearly demonstrated the benefit of allogeneic islet transplantation. Severe hypoglycemia is serious issue not only for type 1 diabetic patients but also type 2 diabetic patients especiall [...]